

SureSeq



A Sysmex Group Company

Innovative NGS myeloid malignancy solutions

From sample to tertiary insights, bring clarity to your workflow

At OGT, we develop pioneering hybridization technology that fits seamlessly into your workflows. Leveraging rational, expert-driven development, our SureSeq myeloid range offers:

- **Enhanced detection of complex structural variants** – including those that are difficult for amplicon-based approaches
- **Better coverage uniformity** – even for hard-to-sequence GC rich regions of the genome
- **Clearer genetic profile of your sample** – with more unique fragments detected and reduced bias and error



Simplify the way you work with NGS

Traditional research approaches for myeloid malignancies can consign your laboratory to complex and time-consuming multi-stage workflows.

Our SureSeq™ myeloid malignancy research solutions are underpinned by a universal workflow compatible across all disease areas and product applications, unlocking the simplicity and efficiency you need. With our NGS myeloid solutions you also reap the benefits of reliably detecting *FLT3*-ITDs so you can free yourself from additional testing.

Experience our fast, cost-effective myeloid NGS solutions and bring clarity to your workflow



1. Sample preparation



2. Genetic sequence



3. Variant detection
with Interpret software



4. Tertiary analysis
with Intelliseq

Empowering you with the latest developments

Be assured you're capturing the most important targets with SureSeq panels designed in collaboration with leading cancer experts

Delivering exceptional uniformity

Confidently detect low-frequency SNVs and indels with our best-in-class design process, informed by our unique expertise, for exceptionally uniform coverage

Robust detection of challenging biomarkers

Analyze difficult biomarkers, including *CEBPA*, *NPM1*, *FLT3*-ITDs (even up to 300 bp)¹ and *KMT2A*, with our hybridization-based approach and remove the need for supplementary approaches

Seamless customization at the touch of a button

Access a library of over 1000 pre-optimized targets or request novel targets, so you only sequence the biomarkers that matter most to you

OGT has you covered no matter your research or myeloid malignancy focus. With our broad range of NGS products we cover the full myeloid disease spectrum, so we have the solution for you, every time.

With SureSeq, you can alleviate the burden of running multiple assays in a single panel. Our expertly designed NGS solutions provide outstanding coverage uniformity so you can robustly detect:

- Low frequency SNVs and indels
- *FLT3*-ITDS, even for those as long as 300 bp
- *KMT2A*-PTDs of all sizes

Visit ogt.com/myeloid-ngs or use the QR code to find out more.



SureSeq Core MPN Panel

Robustly detect key variants associated with MPN, with the flexibility to include *BCR-ABL* fusion gene detection.

Product Code

780001-24, 780001-96

Reactions

24, 96

Panel Size

1 Kb

Number of Targets

3 key clinically relevant genes (\pm *BCR-ABL* fusion)

SureSeq Myeloid Plus Workflow

Accurately detect clinically relevant SNVs, indels and structural variants, even in challenging biomarkers, for a wide variety of myeloid malignancies.

Product Code

780002-24, 780002-96

Reactions

24, 96

Panel Size

132 Kb

Number of Targets

49 genes (+4 sex chromosome genes)

SureSeq Pan-Myeloid Panel

Obtain a comprehensive picture of the genetic make-up of every myeloid sample you run.

Product Code

780003-24, 780003-96

Reactions

24, 96

Panel Size

221 Kb

Number of Targets

70 genes (+4 sex chromosome genes)

SureSeq Myeloid Fusion Panel

Coming soon

Simultaneously detect all fusions of baited genes and enhance sample classification with novel/rare fusions.

Product Code

890001-24, 890001-96

Reactions

24, 96

Panel Size

61 Kb

Number of Targets

30+ fusions (+ partner gene-agnostic fusion detection for detection of novel fusion partners)

SureSeq Myeloid MRD Panel

Coming soon

Comprehensively interrogate a wide range of targets with highly sensitive detection down to 0.05% VAF.

Product Code:

780126-48, 770026-48

Reactions:

12, 12

Panel Size

11.2 Kb

Number of Targets

13 genes

SureSeq myPanel Custom AML Panel

Create your ideal panel with our sophisticated bait design strategies and sequence only what's relevant for your AML research.

Product Code

Upon request

Reactions

Upon request

Panel Size

Upon request

Number of Targets

Contact our team to begin designing your panel

Unlock the full potential of NGS tertiary analysis

Unparalleled genomic interpretation and report generation

With OGT unlock comprehensive end-to-end myeloid analyses, from sample to report. Our partnership with Intelliseq, a leading genome informatics company, brings you the innovation and expertise your research demands.

With our tertiary analysis solution, you can:

- Access ready-to-use report templates for myeloid malignancy panels
- Generate easily digestible insights with automated report generation
- Be assured of trustworthy results from up-to-date databases
- Customize your NGS analysis or report to suit your specific cancer research needs

Intelliseq GeneSpect Report for Myeloid Cancer
Signal: WB

Not provided Not provided

Age: 72 | Sample ID: demo_sample_001 | Ordering physician: Not provided

Tumor type: Blood cancer | Patient ID: Not provided | Specimen type: Not provided

Summary of the results

TIER I VARIANTS					
Gene	Mutation	AR / VAF	AMP/ASCO/CAP classification	FDA On-Label Therapy	Associated malignancy*
DNMT3A	NM_022352.5:c.1904G>A (p.Arg335Gln)	0.0124 / 0.0123	Tier IA	Not available	AML, CHIP, CCUS
SF3B1	NM_012433.4:c.1886G>C (p.Glu622Asp)	0.0124 / 0.0123	Tier IA	Not available	AML, CLL, MDS
TET2	NM_001127208.3:c.3407delT (p.Glu1137fs)	0.0124 / 0.0123	Tier IA	Not available	AML, MDS, CMML, CHIP, CCUS
FLT3	NM_004119.3:c.2593G>T (p.Arg835Tyr)	0.0124 / 0.0123	Tier IA	Gilteritinib, Quizartinib, Midostaurin	AML

TIER II VARIANTS					
Gene	Mutation	AR / VAF	AMP/ASCO/CAP classification	FDA Off-Label Therapy	Associated malignancy*
NPM1	NM_002320.7:c.58G>T (p.Gly20Cys)	0.0124 / 0.0123	Tier BC	Not available	AML, MDS

Risk category**
POOR/ADVERSE-RISK AML

Prognostic factors
FLT3 TKD mutation and adverse-risk genetic lesion: SF3B1

FDA RECOMMENDATIONS
Option 1) **Gilteritinib**

Biomarker: **FLT3**

Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3-like tyrosine kinase 3 (FLT3) mutation as detected by a FDA-approved test.

Page 1/25 | For Research Use Only. Not for use in diagnostic procedure. | Generated: 03/20/2024

Start your NGS journey with OGT today

Contact one of our Myeloid NGS experts to discuss your project requirements. Visit ogt.com/myeloid-ngs or use the QR code to find out more.



Ordering information

UK +44 (0) 1865 856800

US +1 914 467 5285

contact@ogt.com

ogt.com

References

1. Milner N et al. Development of a target-capture NGS assay for use in molecular-based research of myeloid measurable residual disease (MRD). Oxford Gene Technology. 2023. Available at: <https://www.ogt.com/resources/ngs-resources-support/ngs-scientific-literature/>



A Sysmex Group Company

What binds us, makes us.

Oxford Gene Technology Inc., 520 White Plains Road, Suite 500, Tarrytown, NY 10591, USA

SureSeq: © Oxford Gene Technology IP Limited – 2024. All rights reserved. SureSeq™: For Research Use Only. Not for Use in Diagnostic Procedures. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representatives for availability. iFlow™ and GeneSpect™ Somatic Reporter: For Research Use Only. Not for Diagnostic Procedures. These products are the exclusive property of Intelliseq and are protected by all applicable legal rights and regulations